- D1532C00016 (AZD): "A phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of AZD6244 (Hyd-Sulfate) in combination with docetaxel, compared with docetaxel alone, in second-line in patients with KRAS mutation positive locally advanced or metastatic (stage IIIB- IV) non-small-cell lung cancer”
- 1200.70 (BIBW 2992): “An open label phase IB clinical trial of continuous once daily oral treatment using BIBW 2992 plus sirolimus (Rapamune®) in patients with non-small-cell lung cancer harboring an EGFR mutation and/or disease progression following prior erlotinib (Tarceva®)” - active
- BREC: "Phase III multicenter randomized trial to evaluate individualized treatment evaluating BRCA1 in cancer patients with advanced non-small-cell lung cancer. BREC Study (BRCA1 expression customization)” - active
- EURTAC: “Phase III, multicenter, open label, randomized trial with erlotinib (Tarceva®) vs. chemotherapy to treat advanced non-small cell lung cancer in patients with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)”
- PM2734-A-003-08 (IRVALEC): “Phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic trial of PM02734 administered in combination with erlotinib in patients with advanced malignant solid tumors” - active
- 1200.75 (BIBW 2992): "LUX-Breast1; Phase III, randomized, open-label clinical trial of Vinorelbine+ BIBW 2992 vs. Vinorelbine + trastuzumab in HER2 overexpressing metastatic breast cancer patients after failing trastuzumab treatment “ - active
- MK 0000-083: “A multicenter phase IB trial to measure [18F]-Fluorodeoxyglucose uptake by positron emission tomography in stage IIIB and IV non-small-cell lung cancer before and after chemotherapy with gemcitabine and cisplatin or carboplatin”
- MK 0646-008: “A phase IB, multicenter trial to evaluate molecular determinants of response to erlotinib and MK-0646 in advanced non-small-cell lung cancer”
- 1199.15: “Multicenter, randomized, double-blind phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer” - active
- SAVE ONCO: “A multinational, randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk of VTE and who are undergoing chemotherapy”
- SCAT: “Randomized trial of customized adjuvant chemotherapy based on BRCA1 mRNA levels in stages II-IIIA non-small-cell lung cancer patients” - active
- STRACT: “Phase II clinical trial of trabectedin after progression to anti-tumoral platinum-based therapy in advanced non-small-cell lung cancer (NSCLC) patients with overexpression of XPG and/or ERCC1, and underexpression of BRCA1”
- TARZO: “Sequential phase I/II trial of oral vorinostat (MK 0683) in combination with erlotinib in non-small-cell lung cancer (NSCLC) patients with mutations at epidermal growth factor receptor (EGFR) with disease progression after erlotinib treatment” - active
- ANGIOMED: “Pharmacogenomic trial to investigate the relationship between angiogenic markers and treatment response to carboplatin, paclitaxel and bevacizumab in first-line in advanced non-small cell lung cancer patients with predominant non-squamous histology” - active
